Medicine & Life Sciences

1. Graft vs Host Disease 100%
2. Cell Transplantation 52%
3. Allogeneic Cells 43%
4. Primary Myelofibrosis 40%
5. National Institutes of Health (U.S.) 36%
6. Survival 31%
7. Transplantation 21%
8. Quality of Life 19%
9. Transplants 18%
10. Stem Cell Transplantation 17%
11. Mortality 16%
12. Polycythemia Vera 15%
13. Busulfan 15%
14. Bronchiolitis Obliterans 14%
15. Patient Reported Outcome Measures 13%
16. INCB018424 13%
17. Hematopoietic Stem Cell Transplantation 12%
18. Clinical Trials 11%
19. Skin 10%
20. Therapeutics 10%
21. Myelodysplastic Syndromes 10%
22. Multiple Myeloma 10%
23. Neoplasms 10%
24. Confidence Intervals 9%
25. Bone Marrow 9%
26. Acute Myeloid Leukemia 9%
27. fludarabine 9%
28. Homologous Transplantation 7%
29. Rituximab 7%
30. Steroids 7%
31. Lung 7%
32. RG7388 7%
33. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6%
34. Melphalan 6%
35. Consensus 6%
36. Practice Guidelines 6%
37. trans-crotonin 6%
38. Comorbidity 6%
39. Recurrence 5%
40. Walk Test 5%
41. Karyotype 5%
42. Splenomegaly 5%
43. GATA2 Deficiency 5%
44. Bone Marrow Transplantation 5%
45. Amphiregulin 5%
46. venetoclax 5%
47. Sclerosis 5%
48. montelukast 5%
49. Fascia 5%
50. Janus Kinase Inhibitors 5%